RESEARCH ARTICLE


Long-Term Survivors with Metastatic Uveal Melanoma



Dominic M Buzzacco§, 1, Mohamed H Abdel-Rahman§, 1, 2, Stanley Park 1, Frederick Davidorf 1, Thomas Olencki 3, Colleen M Cebulla*, 1
1 Department of Ophthalmology and Vision Science, The Ohio State University, Columbus, Ohio, USA
2 Department of Internal Medicine, Division of Human Genetics, The Ohio State University, Columbus, Ohio, USA
3 Department of Hematology Oncology, The Ohio State University, Columbus, Ohio, USA


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1767
Abstract HTML Views: 1752
PDF Downloads: 233
Total Views/Downloads: 3752
Unique Statistics:

Full-Text HTML Views: 734
Abstract HTML Views: 818
PDF Downloads: 167
Total Views/Downloads: 1719



© Buzzacco et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Ophthalmology and Vision Science, The Ohio State University, 915 Olentangy River Road, Suite 5000, Columbus, Ohio 43212, USA; Tel: 614-652-2600; Fax: 614-652-2610; E-mail: colleen.cebulla@osumc.edu
§ These authors contributed equally to the manuscript.


Abstract

Background:

To report the tumor, patient, and treatment characteristics of long-term metastatic uveal melanoma survivors.

Methods:

A non-comparative, retrospective case series of patients from a single institution surviving >24 months with metastatic uveal melanoma (UM).

Results:

Nine patients met the study criteria and their charts were reviewed. The mean age at diagnosis of UM was 44.1 years (SD +/- 14.4 years). Initial treatment modalities included enucleation (67%), brachytherapy (22%), and proton beam radiation (11%). The average time from primary tumor diagnosis to detection of metastasis was 125.9 months (SD +/- 95 months). The most common location for initial metastasis was the liver. All patients underwent treatment for metastatic disease including systemic therapy, surgical resection, and isolated hepatic perfusion. The majority of patients received treatment with a tyrosine kinase inhibitor (sorafenib, sunitinib, and/or imatinib). The median survival with metastasis was 51 months (range 27-123 months). Patients had a long disease-free interval before presentation of metastatic disease.

Conclusions:

A small subset of patients with metastatic UM has prolonged survival. Identification of these patients may be helpful for future clinical trial design.

Keywords: Tumor, uveal melanoma, metastasis, alanine transaminase, transpupillary thermal therapy and chemotherapy.